Clinical efficacy of sitagliptin phosphate combining metformin in different doses in treatment of type 2 ;diabetes mellitus
YAO Lu
ZHANG Wei
WU Yun-tao
TIAN Guo-xiang
WANG Xiao-bing
XIA Chang-quan
ZHANG Feng
Abstract：Objective To observe the curative effect and safety of sitagliptin phosphate combining metformin in different doses in treatment of type 2 diabetes mellitus (T2DM). Methods T2DM patients (n=90, male 52, female 38, aged from 28 to 74 and average age=51.5±9.3) were chosen from Sept. 2012 to Nov. 2014, and divided randomly into low-dose combining group, high-dose combining group and single drug group (sitagliptin phosphate, each n=30). The levels of fasting blood glucose (FBG), 2-hour postprandial blood glucose (2-hPBG) and glycated hemoglobin (HbAlc) were compared in 3 groups before and after treatment for 24 w. The adverse reactions including hypoglycemia and gastrointestinal discomfort were recorded. Results The levels of FBG, 2-hPBG and HbA1c decreased in low-dose combining group and high-dose combining group compared with single drug group after treatment for 24 w (all P<0.05). The hypoglycemic effect was significant in high-dose combining group compared with low-dose combining group (P>0.05). There was each 1 case of hypoglycemia respectively in 3 groups (3.33%vs. 3.33%vs. 3.33%, P>0.05), and 1 case of gastrointestinal discomfort in high-dose combining group and alleviated gradually until disappeared without any special treatment. Conclusion Sitagliptin phosphate combining metformin has more significant hypoglycemic effect than single sitagliptin phosphate with higher safety.
Keywords：Type 2 diabetes mellitusSitagliptin phosphateMetformin
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 807-808,811 )